Paper Details

  1. Home
  2. Paper Details

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.

Author: EngertAndreas, MonsefIna, RanceaMichaela, SkoetzNicole, von TresckowBastian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Hodgkin lymphoma (HL) is a common cancer in young adults and is curable for most people, even in advanced stages. However, about 15-20% don't respond to initial treatment and experience a relapse. For these patients, a common treatment is high-dose chemotherapy followed by a stem cell transplant.
Paper Details　
Original Abstract of the Article :
Hodgkin lymphoma (HL) is one of the most common malignancies in young adults and has become curable for the majority of patients, even in advanced stage. After first-line therapy, 15% to 20% do not respond to treatment and relapse. For those patients, high-dose chemotherapy (HDCT) followed by autolo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD009411.pub2

データ提供：米国国立医学図書館（NLM）

High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin lymphoma (HL) is a common cancer in young adults and is now curable for the majority of patients, even in advanced stages. However, about 15-20% of patients relapse after initial treatment. For these patients, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a frequent treatment option. This study explores the use of high-dose chemotherapy and stem cell transplantation for Hodgkin lymphoma. It delves into the efficacy of this approach, the clinical outcomes observed, and the potential benefits for patients with relapsed/refractory HL. The authors provide a valuable overview of this treatment modality and its implications for patients facing this challenging condition.

Understanding the Complexities of Hodgkin Lymphoma Treatment

This research sheds light on the complex landscape of Hodgkin lymphoma treatment. The study highlights the fact that while there is considerable progress in treating this type of cancer, relapse remains a significant concern. It also emphasizes the critical role of high-dose chemotherapy and stem cell transplantation in addressing relapsed or refractory cases. The study's findings offer a nuanced perspective on the challenges and opportunities presented by this treatment approach.

The Importance of Stem Cell Transplantation in Cancer Therapy

This research underscores the importance of stem cell transplantation in cancer treatment. It demonstrates how this technique can be effectively utilized to restore bone marrow function following high-dose chemotherapy. This is particularly crucial for patients with relapsed/refractory Hodgkin lymphoma, as their immune systems are compromised. Stem cell transplantation offers a chance for recovery and a potential path towards long-term remission.

Dr. Camel's Conclusion

Imagine a vast desert landscape, where each grain of sand represents a complex medical challenge. This study acts as a compass, guiding us through the intricacies of treating relapsed/refractory Hodgkin lymphoma. It underscores the significant role of high-dose chemotherapy and stem cell transplantation in this challenging realm, offering valuable insights into a complex medical journey.
Date :
  1. Date Completed 2013-11-19
  2. Date Revised 2018-12-21
Further Info :

Pubmed ID

23784872

DOI: Digital Object Identifier

10.1002/14651858.CD009411.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.